Karim M, Prey J, Willer F, Leiner H, Yasser M, Dombrowski F
Int J Mol Sci. 2025; 26(5).
PMID: 40076869
PMC: 11900174.
DOI: 10.3390/ijms26052246.
Yang L, Li P, Zhao J, Bai Z, Zeng G, Liu X
Discov Oncol. 2025; 16(1):272.
PMID: 40053253
PMC: 11889291.
DOI: 10.1007/s12672-025-02051-y.
Biagioli M, Fiorucci S
Liver Res. 2025; 5(3):119-141.
PMID: 39957845
PMC: 11791866.
DOI: 10.1016/j.livres.2021.08.003.
Fernandez-Ramos D, Lopitz-Otsoa F, Lu S, Mato J
Cancers (Basel). 2025; 17(3).
PMID: 39941901
PMC: 11816870.
DOI: 10.3390/cancers17030535.
Jiang Y, Chen J, Xu L, Lv L, Gan X
J Cancer. 2025; 16(3):917-931.
PMID: 39781352
PMC: 11705051.
DOI: 10.7150/jca.100724.
Genetic associations of plasma metabolites with immune cells in hyperthyroidism revealed by Mendelian randomization and GWAS-sc-eQTLs xQTLbiolinks analysis.
Li Y, Song X, Huang Y, Zhou S, Zhong L
Sci Rep. 2025; 15(1):1377.
PMID: 39779799
PMC: 11711443.
DOI: 10.1038/s41598-025-85664-1.
Innate immune cells link dietary cues to normal and abnormal metabolic regulation.
Zhang P, Watari K, Karin M
Nat Immunol. 2025; 26(1):29-41.
PMID: 39747429
DOI: 10.1038/s41590-024-02037-y.
Biomarkers and potential therapeutic targets driving progression of non-alcoholic steatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis.
Fan H, Wang R, Wen B, Xiong J
Front Immunol. 2024; 15:1502263.
PMID: 39697329
PMC: 11652351.
DOI: 10.3389/fimmu.2024.1502263.
Causal associations of immunophenotypes with metabolic dysfunction-associated fatty liver disease and mediating pathways: a Mendelian randomization study.
Xie K, Chen M, An H, Gao J, Tang C, Huang Z
Ther Adv Chronic Dis. 2024; 15:20406223241303649.
PMID: 39669435
PMC: 11635899.
DOI: 10.1177/20406223241303649.
Blocking interleukin-1 receptor type 1 (IL-1R1) signaling in hepatocytes slows down diethylnitrosamine-induced liver tumor growth in obese mice.
Gehrke N, Hofmann L, Straub B, Ridder D, Waisman A, Kaps L
Hepatol Commun. 2024; 8(12).
PMID: 39621069
PMC: 11608749.
DOI: 10.1097/HC9.0000000000000568.
N6-methyladenosine regulators in hepatocellular carcinoma: investigating the precise definition and clinical applications of biomarkers.
Yan X, Qi Y, Yao X, Yin L, Wang H, Fu J
Biol Direct. 2024; 19(1):103.
PMID: 39511687
PMC: 11542411.
DOI: 10.1186/s13062-024-00554-2.
Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice.
Tao S, Lei Y, Tan Y, Yang Y, Xie W
Front Med (Lausanne). 2024; 11:1476419.
PMID: 39440040
PMC: 11493624.
DOI: 10.3389/fmed.2024.1476419.
Active role of the immune system in metabolic dysfunction-associated steatotic liver disease.
Mori T, Yoshio S, Kakazu E, Kanto T
Gastroenterol Rep (Oxf). 2024; 12:goae089.
PMID: 39411101
PMC: 11479709.
DOI: 10.1093/gastro/goae089.
Immunological dynamics in MASH: from landscape analysis to therapeutic intervention.
Rabiu L, Zhang P, Afolabi L, Saliu M, Dabai S, Suleiman R
J Gastroenterol. 2024; 59(12):1053-1078.
PMID: 39400718
DOI: 10.1007/s00535-024-02157-0.
Macrophages and T cells in metabolic disorder-associated cancers.
Taranto D, Kloosterman D, Akkari L
Nat Rev Cancer. 2024; 24(11):744-767.
PMID: 39354070
DOI: 10.1038/s41568-024-00743-1.
Single-cell RNA sequencing reveals anti-tumor potency of CD56 NK cells and CD8 T cells in humanized mice via PD-1 and TIGIT co-targeting.
Liu W, Harden S, Tan S, Tan R, Fong S, Tan S
Mol Ther. 2024; 32(11):3895-3914.
PMID: 39318093
PMC: 11573594.
DOI: 10.1016/j.ymthe.2024.09.025.
The immune microenvironment of steatotic hepatocellular carcinoma: Current findings and future prospects.
Cheu J, Chak-Lui Wong C
Hepatol Commun. 2024; 8(9).
PMID: 39225682
PMC: 11371312.
DOI: 10.1097/HC9.0000000000000516.
LUBAC enables tumor-promoting LTβ receptor signaling by activating canonical NF-κB.
Chen Y, Rieser E, Bhamra A, Surinova S, Kreuzaler P, Ho M
Cell Death Differ. 2024; 31(10):1267-1284.
PMID: 39215104
PMC: 11445442.
DOI: 10.1038/s41418-024-01355-w.
miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression.
Fernandez-Tussy P, Cardelo M, Zhang H, Sun J, Price N, Boutagy N
JCI Insight. 2024; 9(19).
PMID: 39190492
PMC: 11466198.
DOI: 10.1172/jci.insight.168476.
From MASLD to HCC: What's in the middle?.
Provera A, Vecchio C, Sheferaw A, Stoppa I, Pantham D, Dianzani U
Heliyon. 2024; 10(15):e35338.
PMID: 39170248
PMC: 11336632.
DOI: 10.1016/j.heliyon.2024.e35338.